Members

Aaron is a medical informatics expert and entrepreneur with 35 years of experience focused on healthcare and medical research. 

C. Noel Bairey Merz, MD, MACC, FAHA, FESC holds the Women's Guild Endowed Chair in Women's Health, and is Director of the Barbra Streisand Women's Heart Center, the Linda Joy Pollin Women's Heart Health Program, and the Preventive Cardiac Center at the Cedars-Sinai Smidt Heart Institute, where she is also a Professor of Medicine. Dr. Bairey Merz received her bachelor's degree from the University of Chicago and her medical degree from Harvard University, with subsequent training at University of California San Francisco and Cedars-Sinai Medical Center. An internationally-recognized pioneer and leader in cardiovascular research, advocacy, and education, Dr. Bairey Merz has been at the forefront of many women's heart health research initiatives and has been educating women on how to recognize female-pattern heart disease symptoms. Her research interests include women and heart disease, mental stress and heart disease, the role of exercise, nutrition, cholesterol, and stress management in reversing heart disease, and adverse pregnancy outcomes and cardiovascular disease. Currently, she is chair and principal investigator of the National Institutes of Health (NIH)-sponsored WISE (Women's Ischemic Syndrome Evaluation) initiative, which is investigating potential methods for more effective diagnosis and evaluation of ischemic heart disease in women.

Jennifer Barsky is the Founder and Executive Director of Menoglobal, the leading international organization making menopause a global health priority. A global development leader with over 25 years of experience, she has designed and led transformative initiatives in more than 20 countries. Before founding MenoGlobal, she held senior roles at the World Bank Group and served as the founding director of the Nike Foundation. Widely published, Barsky has advised leading global organizations on women's health, gender equity, and inclusive innovation, and is a network faculty member at the London Interdisciplinary School.

Shay Beider is the founder and CEO of Integrative Touch (InTouch), a non-profit organization that operates an international healing center for individuals experiencing high impact trauma and illness. She pioneered the Health-caring wellness model and Integrative Touch therapy, a comprehensive mind, body, spirit approach that has been shown to significantly improve pain management and psycho-social outcomes. Shay hosts the Conversations on Healing podcast with listeners in over 100 countries, holds a master's degree in public health from UCLA, and has been recognized by the Robert Wood Johnson Foundation as a Pioneer for Children's Wellbeing. She is a sought-after speaker on health and wellness topics and was awarded the Women's Studies Achievement Award from UCLA and the Civic Leadership Award from the Community Foundation for Southern Arizona.

As President of the Catalytic Impact Foundation since 2018, Rachel has guided the growth of the organization to become a philanthropic leader in deploying catalytic capital to accelerate innovation in underfunded areas of healthcare, where there are significant unmet medical needs. These areas of focus include women's health, children's health, and brain/mental health. She has lead the team managing the investment analysis and processes, building a portfolio of more than 50 companies (52% led by women).

Sarah-Almaza Cox is currently the co-founder of Joeyband, a globally patented, FDA-registered medical device that is transforming maternal and newborn health outcomes in hospitals around the world.

With a vision for available, accessible and affordable healthcare for all women in Asia, Lindsay Davis founded FemTech Association Asia, the region's first and largest specialist advisory and industry network. Focused on improving women's health through technology solutions, this award-winning organization represents 80+ startups across 10 countries in Asia.

Meeghan De Cagna, MSc, CAE, DES, is the Chief Program Officer at the American Physiological Society where she provides executive leadership, management, and oversight of the Society's program offerings to ensure alignment with the organization's mission. Leading marketing, communications, policy and advocacy, meetings and events teams, De Cagna drives organization-wide collaboration and stakeholder engagement in service to APS members and the field of physiology. De Cagna has more than 30 years of experience leading scientific and medical education and partnership programs both here in the US and across the globe. She holds a Certified Association Executive designation and a Master of Science in Health Communication from Boston University. She has completed additional training at Villanova, Stanford, Georgetown and Thunderbird Universities.

Yvanka de Soysa is a biomedical scientist turned investor with a passion for leveraging scientific innovation to transform healthcare for women. Yvanka has worked across the life sciences ecosystem at Hevolution Investments, 5AM Ventures, Flagship Pioneering and Harvard's Office of Technology Development. She completed a postdoctoral fellowship in neuroimmunology as a William Randolph Hearst Fellow at Harvard Medical School and earned her PhD in biomedical sciences at UCSF.

Dr. Roberta Diaz Brinton leads the Center for Innovation in Brain Science at the University of Arizona, where she is Regents Professor of Pharmacology, Neuroscience, and Neurology. She earned her Ph.D. as an NIH Predoctoral Fellow at the University of Arizona and completed her NIH Postdoctoral Fellowship at Rockefeller University.

DeChane L. Dorsey is the Executive Director of AdvaMed Accel, a division within the Advanced Medical Technology Association (AdvaMed) representing small and mid-sized companies. She also leads AdvaMed's health access and women's health workstreams. Prior to assuming her current role Ms. Dorsey was a Vice President in the Payment and Health Care Delivery Department at AdvaMed where her responsibilities included policy development and analysis of regulatory issues affecting the medical technology industry. She holds a B.A. in Political Science from Syracuse University and a J.D. from the Georgetown University Law Center.

As Chief Corporate Affairs Officer at Medicines360, Autumn leads corporate engagement activities to bridge the gaps in innovation and access for women's health products. She was part of the original founding team at Medicines360 in 2009. As the original program leader for the organization's first product, the hormonal IUD, Autumn drew on her 15 years of experience bringing new drugs to market to assemble a team and launch the product development plan. Since then, she has dedicated her career to making innovative drugs, devices and combination products more affordable and accessible for women.

Marissa Fayer is a 25-year medtech executive, innovator, entrepreneur, investor, and philanthropist. She is the CEO of DeepLook Medical, CEO and founder of non-profit HERhealthEQ, Investment Committee member of GGVentures, Entrepreneur-in-Residence at Graybella Capital, sits on the board of IMD Medical and on the advisory board of Welwaze Medical, Impact.51, 51&, and the Breast Cancer Early Detection Coalition... all focused on women's health globally. Marissa is a TEDx speaker and speaks globally about investing in women's health innovation. Her mission is to move innovation and the health of women forward throughout the world.

Angelika Fretzen, PhD, MBA, serves as Chief Operating Officer and Technology Translation Director at the Wyss Institute, where she is responsible for effective product development and technology translation from the most innovative ideas into industry-sponsored research, licensing deals and start-up formations (https://wyss.harvard.edu/). In 2022, she founded the Women's Health Catalyst to innovate approaches for advancing the healthcare for women, and in 2024, she received the Joseph B. Martin Dean's Leadership Award for the Advancement of Women's Careers at Harvard Medical School. Before joining the Wyss Institute, Angelika spent two decades in entrepreneurial biotechnology companies, including enabling the pharmaceutical development of Linzess™ at Ironwood Pharmaceuticals and advancing Edasalonexent to Phase 3 clinical trials for the treatment of Duchenne Muscular Dystrophy, at Catabasis Pharmaceuticals. A chemist by training, Angelika completed her undergraduate studies at the Julius-Maximilian's University in Würzburg, Germany, earned her PhD at the University of Geneva in Switzerland, and conducted postdoctoral research at Harvard University as Roche and then Alexander-von-Humboldt Fellow. She holds an MBA from Suffolk University in Boston.

Maya Friedman is a Design Director who designs solutions for unmet needs in the health tech and femtech spaces. She currently leads Tidepool's user experience and design teams. She is also the founder and co-lead of The Tidepool Period Project, which supports the creation of an ecosystem of software solutions, research initiatives, and education to address the unmet needs of women with diabetes, through the different phases of a woman's life cycle including menstruation and pregnancy. Maya has her MFA in Media Design practices with a focus on women's health tech design from ArtCenter College of Design.

Joanne Gan is an impact investing leader and social justice champion, with two decades experience spanning the US and emerging markets. She is currently an investor at Soros Economic Development Fund where she leads its investments in women's health and rights. Prior to SEDF, Joanne was the Head of Impact Investing & ESG, Treasury at PayPal where she led a $500M investment portfolio to advance economic opportunity. Throughout her career, she has held finance and investment roles at Deutsche Bank, Bridges Fund Management, Kiva, and Barclays Capital. Joanne serves on the Board of Aeris Insight, the leading data organization for the U.S. CDFI industry, and is an advisor for the Turner MIINT (MBA Impact Investing Network & Training) program. She holds a MS in Management Science & Engineering and BA in Economics and International Relations from Stanford University.

Elizabeth Garner is a seasoned pharmaceutical executive with a career-long focus on addressing unmet medical needs for women. She is currently CEO of Sena Therapeutics, a start-up company focused on precision medicines for endocrine diseases; Sena's first indication is in PCOS, a prevalent condition with no approved products. Dr. Garner is also Past President of the American Medical Women's Association, a professional organization for women doctors, a Founder and Steering Committee member of Women's Health Advocates, an organization dedicated to improving the health of women, and is a strategic advisor for Women's Health Access Matters (WHAM). She received joint M.D. and M.P.H. degrees from Harvard Medical and Public Health Schools, trained in obstetrics and gynecology at Brigham and Women's (BWH)/Massachusetts General Hospitals, and completed a fellowship in gynecologic oncology at BWH/Dana Farber Cancer Institute.

Pamela D. Garzone is a respected pharmaceutical executive with a significant record of achievement in drug development and leadership, ascending to the C-suite and as an Independent Director. Pamela is a member and co-chair of the selection committee of AIM-HI Women's Venture Competition of the National Foundation for Cancer Research. She is on the leadership committee of Women's Health Advocates and is an active angel investor in women's health companies. Pamela serves on 1 public and 2 private companies' board of directors, serving as chairwoman of a private company developing technologies that address women's health issues. Pamela has achieved the prestigious Qualified Risk Director designation.

Dr. Golomb is a Partner and Founder of InnovaHealth Partners, LP, a leading firm in medical device private equity. In this role she manages private equity investments and the investing process of the firm. Dr. Golomb is Chair of the Women's Health company, Materna Medical, where she has led the last two rounds of financing. She is also the Chair of Radiaction Medical Ltd. Board of Directors and a member of the Board of Directors of Route 92 Medical, Koelis, SAS, the Executive Council of the Department of Health Policy and Management at the Harvard School of Public Health and the Trustees Council of Penn Women.

Currently CEO of IgGenix, a clinical stage antibody discovery and development company focused on immunology. Former CEO of Medicines360, current board member of Dare Biosciences and Founder of Gynesonics. Deep experience in women's health with a distinguished career in the biotechnology, pharmaceutical, and medical device industries. A physician-executive with a proven track record of leading companies from early-stage development to successful commercialization and acquisition. Expertise in fundraising, product development, clinical strategy, and market access, with a dedicated focus on advancing healthcare for women. Holds numerous patents and has successfully raised significant capital to drive medical innovation and improve patient outcomes.

Dr. Tamar Gur is the Inaugural Endowed Director of the Soter Women's Health Research Program, initiated by a pledge of $15 Million to the Ohio State University College of Medicine. She leads innovative research efforts focused on women's health across the lifespan, with a particular emphasis on the impact of stress and the microbiome. Her translational research investigates how prenatal stress, microbiota, and inflammation influence brain development and long term health, utilizing both rodent models and clinical cohorts. Supported by major organizations such as NIH, Dr. Gur's work bridges clinical care and scientific discovery to advance understanding and treatment of women's health.

Dr. Rodney C. Haring is the inaugural Chair of the Department of Indigenous Cancer Health at Roswell Park Comprehensive Cancer Center, an NCI-designated institution. A citizen of the Seneca Nation (Beaver Clan), he lives between the Allegany and Cattaraugus Territories. With over 20 years of experience, his work advances resiliency, data sovereignty, health behavior interventions, and translational science while mentoring future cancer scientists. He co-leads Roswell Park's health communications team, producing documentary-style films that support clinical trials and public health. Recognized with national honors including the National Indian Health Board Impact Award, the National Federation of Just Heroes Award, and a TED Ignite Fellowship he is also among the few traditional Haudenosaunee wooden lacrosse stick makers with works exhibited worldwide.

Alessandra Henderson is an entrepreneur, thought leader and investor on a mission to transform women's healthcare. Alessandra is Co-founder & former CEO of Elektra Health, a virtual care platform closing the menopause care gap via evidence-based telemedicine, education and community. Under her tenure as Elektra CEO, Alessandra raised $7M+ from leading investors including University of Pittsburgh Medical Center (UPMC), Flare Partners and Seven Seven Six, built a membership across 50 states, and led Elektra's go-to-market strategy, including launching the first commercial menopause-payer partnership in the US with Mass General Brigham Health Plan. Prior to Elektra Health, Alessandra spent 10+ years building early-stage consumer businesses as a leader on the founding teams at Artsy, the MIT NYC Startup Studio, and Human Ventures. She holds a B.A. from Vanderbilt University and an MBA from MIT Sloan, and her work has been covered by The NY Times, Fast Company, Bloomberg, Techcrunch, Fortune, Forbes, and more. Alessandra currently advises and consults with high growth digital health companies in the pursuit of improving outcomes & redefining a new standard of care. 

Dr. Howard received her MD, MPH from Johns Hopkins, completed residency at UPMC-Magee Women's hospital and fellowship at the University of Michigan. She is a Fellow of the American College of Obstetricians and Gynecologists, a Certified Physician Executive, and a Fellow of the American Association for Physician Leadership. She has served in leadership roles in academic, private and international settings. Dr. Howard's work involve multidiscipline collaboration to leverage technology and innovation to deliver equitable care, reduce physician burnout and improve operational efficiency. 

Emily Jacobs is a Professor of Neuroscience at UC Santa Barbara and Director of the Ann S. Bowers Women's Brain Health Initiative, an endowed research consortium headquartered at UC Santa Barbara and spanning 10 institutions. Her body of research is redefining our understanding of the brain's capacity to undergo dynamic neuroanatomical changes and plasticity well into adulthood. In 2024 her team published the first detailed map of the human brain across pregnancy and she leads several multi-center studies on neurological changes tied to menopause. Prior to UCSB, she held a faculty appointment at Harvard Medical School and the Department of Medicine/Division of Women's Health at Brigham & Women's Hospital. Dr. Jacobs' serves on the Steering Committee of the Coalition for Women's Brain Health, the Foundation for Women's Health, and the WHAM Research Collaborative to drive the national and international agenda on women's health research. You can find her work in The New York Times, National Geographic, Scientific American, NPR, BBC, TED, Netflix, and MasterClass. She is a graduate of Smith College and UC Berkeley.

Alyssa Jaffee is a Partner at 7wire Ventures where she invests in companies that empower everyone to be better stewards of their health. She currently holds board roles at NOCD, MedArrive, Brightline, Zerigo Health, Jasper Health, Summer Health, Transcarent, and the National Venture Capital Association (NVCA). Beyond her investment work, Alyssa is actively involved in the broader healthcare and business communities. She is a member of the Business Leadership Council at WBEZ Chicago, the Oliver Wyman Leaders Alliance, the Economic Club of Chicago, and serves as a venture board member of Health Tech 4 Medicaid.

Priyanka is the co-founder & CEO of Evvy, a precision medicine company leveraging the vaginal microbiome to improve women's health outcomes. Evvy serves over 75,000 patients and has built the world's largest dataset on the vaginal microbiome designed to unlock novel solutions across infertility, preterm birth, gynecological cancers, and more.

Anna is an accomplished diagnostics leader and co-founder of AOA Dx, recognized for her passion for advancing healthcare through innovative diagnostic solutions. Named to Inc. Magazine's 2022 Female Founders 100 List, she brings extensive global and regulatory expertise, having guided multiple products into U.S. and European guidelines and led FDA submissions for 510(k), PMA, and CLIA LTD pathways. With experience launching transformative women's health diagnostics across Europe, the Middle East, Latin America, and Asia, Anna offers a truly international perspective on driving innovation in healthcare.

Dr. Kamphaus serves in the dual role of leading FNIH Patient Engagement efforts and providing oversight to the several programs within FNIH's Metabolic Disorders, Women's Health and Inflammation and Immunity portfolios. In her role as FNIH's Patient Engagement lead, she is responsible for establishing best practices for engaging patient voices for meaningful, end-to-end patient involvement in FNIH programs. Within Science Partnerships, she is responsible for developing multi-stakeholder public-private partnerships that include stakeholders from NIH, FDA, non-profits and life sciences companies. Dr. Kamphaus oversees three target validation programs within Accelerating Medicines Partnerships (AMP) programs in areas of Common Metabolic Diseases, Heart Failure, and Immune and Autoimmune Diseases. She also oversees projects including biomarker qualification efforts in liver diseases, preeclampsia, osteoporosis, and emerging programs in reproductive health. Dr. Kamphaus is a preeclampsia survivor and brings her lived experience to her leadership of FNIH's Patient Engagement activities. She is trained in molecular genetics and cell biology and skilled in strategic planning and collaborative program development across basic, translational and patient-centric clinical research. Dr. Kamphaus conducted her postdoctoral fellowship at Columbia University. She has a PhD in Molecular Genetics from The Ohio State University.

Coyote Ventures invests in tech-enabled solutions that drive access to healthcare for overlooked populations, including in women's health. Founded by scientists, entrepreneurs, and investors, Coyote takes an integrative view of health that spans physical, financial, and emotional health. General Partner Jessica Karr was a Biochemist at Impossible Foods and has hands-on experience building and launching novel products.

Dr. Sabra L. Klein is a Professor of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health, where her research focuses on understanding how sex, pregnancy, and aging impact immune responses to microbial infections and vaccines. Her work investigates how gonadal steroids and genes on sex chromosomes impact the immune system. She is a fellow of both the American Academy of Microbiology and the American Association for the Advancement of Science. Dr. Klein has authored over 225 peer-reviewed publications and is recognized among the top 2 percent of researchers worldwide across diverse biomedical fields.

Jennifer Law is the Maternal Health Venture Leader at Philips, a global healthcare technology company that aims to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. In her role, Jennifer focuses on how technology can help close the care gap for millions of pregnant women and families who lack access to quality prenatal and postpartum care in the U.S. and around the world. Philips' portfolio spans medical devices like ultrasound and patient monitoring, as well as consumer products such as the Avent brand and the world's most downloaded pregnancy app.

AccendoWave, a Pain Data Company with machine learning pain measurement & management technology. AccendoWave, a Top 4 Global Best in Class Health Equity Solution and Top 15 Global Best in Class Remote Monitoring Company, benchmarks pain data (specialty, gender, age) with machine learning technology to eliminate bias, improve outcomes and reduce health care costs. Incubated by HCA (188 Hospitals & 6-7% of US Inpatient Care) - Samsung and AT&T are our partners.

Jasmine Lim is a Program Operations Officer with the Soros Economic Development Fund, the impact investing arm of the Open Society Foundations. Prior to joining SEDF, Jasmine worked at the American Civil Liberties Union (ACLU), where she supported the Deputy Executive Director, Strategy and Culture and the Chief People Officer as a Special Assistant. At the ACLU, she played a pivotal role in outlining strategic initiatives, developing internal communications procedures, and fostering organizational culture. Jasmine has also held previous roles at the Center for Strategic and International Studies (CSIS), the Future of Privacy Forum, and the Aspen Institute in Washington, DC. She speaks Korean and Spanish and is an avid traveler, artist, and yoga practitioner. 

Dr. McGinty did her medical training in Ireland at the University of Galway and then came to the USA for residency at the University of Pittsburgh where she was Chief Resident. Her fellowship was in Women's Imaging at the Massachusetts General Hospital. In 2000, she completed an MBA at Columbia University. She is an internationally recognized expert in imaging economics. In May 2018 she was elected as the Chair of the American College of Radiology's (ACR) Board of Chancellors, the first woman to hold this office. She received the ACR's highest honor, its Gold Medal, in 2024. In 2014 she joined the faculty at Weill Cornell Medicine in New York City and in 2021 she was appointed as Senior Associate Dean for Clinical Affairs. Since 2017 she has taught in the combined Weill Cornell Medicine and Cornell SC Johnson School of Business EMBAMS in Healthcare Leadership. She was appointed as Senior Associate Dean for Faculty in 2024. She is a member of the board of 4D Medical (4DX) as well of her alma mater.

Rebecca Osthus, Ph.D. serves as the Director for Government Relations and Science Policy at the American Physiological Society (APS). In this capacity, she represents physiology within the broader biomedical research advocacy community, seeks opportunities to involve physiologists as advocates for science, and ensures that members have access to relevant and timely information about government funding and policies for research. Dr. Osthus earned her doctorate in Human Genetics at the Johns Hopkins University School of Medicine before pursuing a career in science policy.

Oriana Papin-Zoghbi is the CEO and co-founder of AOA Dx and a visionary leader in women's health and diagnostics. Under her leadership, AOA Dx has raised $27 million in funding. Oriana has built and scaled a high-performing, mission-driven team, guiding AOA Dx through early development and rapid organizational growth. Recognized in Inc.'s Top 100 Female Founders for her groundbreaking work in ovarian cancer diagnostics, she brings deep experience launching products globally, from HPV screening programs in East Africa to innovations in oncology, maternal-fetal medicine, and infectious diseases. Oriana holds a degree in Economics and International Relations from Boston University and brings a global perspective to her work.

Karen Patti is a fearless healthcare innovator whose career spans clinical practice, nonprofit administration, and executive leadership at the intersection of women's health and equity. She earned her Bachelor of Arts with honors in English Literature and Spanish from Denison University and a Master of Science from Columbia University. Beginning as a clinician, she quickly advanced into hospital administration before stepping into a transformative leadership role as Chief Operating Officer of the Promise Fund. At the Promise Fund, she has spearheaded multi-million-dollar fundraising campaigns, forged groundbreaking public and private partnerships, and embedded comprehensive cancer prevention and treatment programs into Federally Qualified Health Centers. Known for her vision, grit, and results, Karen is driving a national blueprint to eliminate barriers and deliver dignity in women's healthcare.

Since starting G2G Consulting in 2007 G2G has secured over $550 million in government funding, shaped policy for health and high-tech innovation for businesses and nonprofits, managed grassroots mobilization advocacy campaigns, and secured CMS reimbursement. In 2025, Liz founded Women's Health Advocates, which is a culmination of several coalitions she launched and managed over the past several years. It has members in all 50 states, organized the first-ever Women's Health Capitol Hill Day, and has secured legislative success. Previously, she served as Legislative Director in Congress, a Policy Analyst for the UK House of Commons Health Committee, and as congressional and presidential campaign staff. Awarded the Woman Entrepreneur of the Year and Women of Achievement awards, Liz earned her MPH from Harvard, JD from George Washington, and BA from Colgate.

Since co-founding Spark in 2018, Daniel has led the company's development of wearable neurostimulation solutions designed to address major unmet medical needs in neurological health, hemostasis & bleeding disorders, and women's health. Under his leadership, Spark developed and commercialized the first transcutaneous auricular neurostimulation (tAN®) device to relieve acute opioid withdrawal, The Sparrow Ascent. Followed by the launch of OhmBody, the first ever menstrual wellness product addressing the needs over 1/3 of the women who struggle with heavy menstrual bleeding and painful periods. Spark continues the scientific discovery with over a dozen additional clinical trials underway.

Ana Maria Ramirez (she/her) is the Co-Executive Director of Euki, a nonprofit tech startup that co-creates digital tools with and for communities facing the greatest barriers to sexual and reproductive health care. At Euki she leads the co-design and product development of Euki app, one of the first-ever privacy-focused period tracking apps on the market. Before co-founding Euki, she worked as a social science researcher focused on abortion, menstruation, and HIV and AIDS. She has published her work in academic journals and presented at both academic and tech conferences around the globe. Ana is committed to helping build a world where everyone has private, secure access to resources that empower them to live safe, healthy, pleasurable lives.

Amanda Rice is an entrepreneur and the founder of ARC Consulting, while also serving as a leading voice in the fight for women's health equity. Her advocacy began from personal experience after being diagnosed with cancer three times and denied insurance coverage for fertility preservation prior to chemotherapy and radiation. Amanda self-funded a preservation cycle, but was struck by how many women would be forced to forgo that choice purely due to cost.

Ellen Rudolph is the Co-Founder and CEO of WellTheory, a first-of-its-kind platform on a mission to reverse the autoimmune epidemic. Launched in 2022, WellTheory was born out of Ellen and her co-founders' personal health journeys and built to empower the 50 million Americans navigating autoimmune disease with evidence-based care, education, and community.

Basmah Safdar, MD, is an emergency medicine physician and internationally recognized scientist and clinical trialist in sex-specific research with a focus on microvascular health. She leads Women's Health Research at Yale, the university's interdisciplinary research hub committed to improving the lives of women and men through collaborations to achieve scientific discovery, education, translation, and dissemination. With an eye toward growth and impact, Basmah is incubating relevant research and catalyzing change from bench to patient bedside.

Kathryn "Katie" Schubert has led the Society for Women's Health Research as President & CEO since 2020, driving groundbreaking advocacy for women's health equity including landmark work on including pregnant and lactating populations in research. A consensus builder named among healthcare's most influential policy shapers by Washingtonian magazine, she began her career on Capitol Hill and is an expert in translating scientific research on women and sex differences for patients, clinicians, and policymakers. When not championing women's health, she's with her husband, three kids, and dog George.

Samit Shah, MD, PhD, is an Interventional Cardiologist who specializes in the invasive evaluation of coronary artery disease, coronary physiology, and complex coronary interventions. He has received many honors for patient care and education during his decade plus tenure practicing at Yale New Haven Hospital. His scholarly work has focused on the outcomes of cardiovascular interventions and the invasive assessment of coronary physiology. He is the national co-principal investigator of the DISCOVER INOCA multi-center registry, and has active research projects at Yale regarding the diagnostic yield of invasive coronary physiology testing, ischemic heart disease in women, and the vascular effects of psychological stress. Samit is a twice-funded Women's Health Research at Yale Investigator.

With a career spanning three decades across health inequities, HR change & transformation, government, academia, and the private sector, Diana has led equity-centred change in some of the UK's most influential institutions including the BBC and Amazon. She is the founder of MenoAssess, a digital screening/assessment tool and advisory service, designed to help employers and healthcare providers implement evidence-based, intersectional, inclusive menopause solutions.

Erica S. Spatz, MD, MHS, is a cardiologist and clinical investigator at the Center for Outcomes Research and Evaluation (CORE). Erica is Director of Preventive Cardiovascular Health and Director of Digital Health/Remote Patient Monitoring at Yale School of Medicine. Her research focuses on digital innovation, shared decision-making, and patient and community engagement to improve cardiovascular disease prevention and women's heart health. She is Principal Investigator of Pressure Check, a PCORI-funded study addressing hypertension in the community, and Co-Principal Investigator of EMPOWER, a PCORI-funded study targeting postpartum hypertension and depression.

I'm taking everything I learned over more than 40 years of health policy communications in DC & combining that with my personal experiences of caring for my husband who recently passed away from Lewy Body Dementia. I founded Health Dame as a platform to share what I learned & to learn from others. Previously, I ran my own agency, created the award-winning Disruptive Women in Health Care blog, served as the director of health policy for the National Consumers League, the National Health Policy Forum in GW University, worked in HHS and on the Hill. I served on the boards of the Institute for Music and Neurologic Function with Dr. Oliver Sacks, AcademyHealth's Translation and Dissemination Institute Advisory Committee, and Kaiser Permanente's Institute for Health Policy. I was a contributor to The Hill newspaper, served as strategic advisor for the Foundation of Art and Healing, & in 2015 was named a Woman of Impact. I currently serve on the following boards: Chamber Music Maryland, the Lewy Body Dementia Resource Center, and Physician-Parent Caregivers. I owned an art gallery in Georgetown where I hosted salons--I am a self-described ambassador for the health benefits of music and the arts.

Samantha Sulzer is the Corporate Partnerships Officer at Action Against Hunger, where she leads the organization's work with the private sector to build partnerships that drive both funding and awareness on a global scale. She manages a diverse portfolio of collaborations from multi-year, seven-figure commitments to creative cause marketing campaigns that connect business goals to humanitarian impact. With a background spanning events and partnerships across nonprofit and corporate sectors, Sam brings a mix of strategy, creativity, and relationship-building to her work. She is passionate about developing innovative collaborations that not only fight hunger but inspire lasting change.

Wendy is an "investo-preneur" who has traversed being both an investor and founder. As a Venture Capital Partner at AlleyCorp, she supported founders in raising $300M. At Branch Care, she founded the first collaborative care modeled on increasing fertility care access, where she serves as the co-founder and board partner of Branch Care. At AlleyCorp, she was the first Partner focused on early stage consumer companies investing in a dozen startups and at Branch Care, she was the founding CEO, starting the business from a personal pain point she experienced in her own fertility journey building the organization through its first 15 employees and $7M in venture funding.

Engineer from the University of British Columbia and former member of the Chartered Management Accountants of British Columbia, Moises Uribe has over 20 years of experience in corporate finance, sustainability, and executive management, including his tenure as a Senior Consultant at Deloitte. He has advised governments, Fortune 500 companies, and multilateral organizations across the Americas, Africa, Asia, and Europe, leading valuation processes, portfolio structuring, and the implementation of sustainable financial strategies. During his career at Deloitte, he participated in projects with Grupo EPM, Grupo Bancolombia, Grupo Orbis, Fondo Ashmore, Grupo Argos, and the Ministry of Finance of Colombia.

Misti Ushio is a Managing Partner at Digitalis Ventures. Prior to Digitalis Ventures, Misti was the founder and CEO of TARA Biosystems which was acquired by ValoHealth in 2022. Earlier in her career, Misti has served as Chief Strategy Officer and Managing Director of Harris & Harris Group, a publicly traded venture capital firm, and held management roles at Merck & Company and Columbia University. She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). 

Shuba is the Director of Advocacy and Communications for Menoglobal, the leading international organization making menopause a global health priority. A brand marketing leader with over 20 years of global experience, she has driven strategic rebrands and award-winning campaigns for Fortune 500 companies and high-growth startups across healthcare, consumer packaged goods, and finance spanning $2M to $2B in scale. She led the rebrand of India's largest dedicated women's health clinic, launched services spanning PCOS, fertility, and menopause, and developed campaigns that broke taboos around stigmatized women's health conditions.

Deidre Washington serves as AdvaMed's Director, Health Equity, a role she started in 2023. She works on health access issues to help advance AdvaMed's mission of ensuring access to medical technology by all patients to improve their health outcomes. Deidre also works on AdvaMed's Women's Health Initiative, which is dedicated to raising awareness around the importance of women's health, as well as addressing gaps in care.

Kelly Watson is the Vice President of Product & User Experience at Tidepool, a digital health nonprofit developing solutions for people with diabetes. Guided by the belief that patients should help design the tools that shape their health, she has helped Tidepool grow to serve more than 850,000 patients and clinicians and has built partnerships across the medical device and technology landscape. She also helped bring Tidepool Loop a first-of-its-kind, interoperable automated insulin delivery to landmark FDA clearance, marking a milestone for patient-led innovation.

Renee D. Wegrzyn, PhD, is the Co-Founder of Transfyr, an AIxBio company focused on making science more interpretable, robust, and transferable by reducing science friction — the bottlenecks that get in the way of breakthroughs. Previously, she served as the inaugural director of ARPA-H (2022-2025), where she built the agency from the ground up, led a $4B portfolio advancing health innovation, and launched the catalytic ARPA-H Sprint for Women's Health. Her career spans leadership roles at Ginkgo Bioworks and DARPA, with recognition including the Superior Public Service Medal and TIME's Top 100 Innovators list.

Flory has spent her career activating the business community to be great stewards for all their stakeholders. In 2022, she launched Reproductive & Maternal Health Compass (RMH Compass), a non-profit focused on expanding the reproductive and maternal health (RMH) benefits available to U.S. workers. Their goal is for all U.S. employers to provide comprehensive RMH benefits to their whole workforce.

Dr. Jocelyn R. Wittstein is an Associate Professor of Orthopaedic Surgery at Duke University, specializing in sports medicine. Her clinical and research interests span the shoulder, elbow, and knee in both pediatric and adult populations with focus on the female athlete across the lifespan, post traumatic arthritis after knee injuries, and the musculoskeletal syndrome of menopause and its repercussions. She is an NIH funded researcher in the field of post traumatic arthritis, co-author of The Complete Bone and Joint Health Plan, and a leader in the Duke Female Athlete Program as well as co-PI on several studies with Dr. Anne Ford of Duke Women's Health looking at joint health, frozen shoulder, and musculoskeletal benefits of hormone therapy in menopausal women. She is also president of the Forum: Women in Sports Medicine, a national organization of female orthopaedic surgeons subspecialized in sports medicine.

Dr. Summia Zaher is CEO of Women and Children's Care at M42 and also serves as CEO of M42's Danat Al Emarat Hospital.

I am a physician, educator, published author, angel investor and "accidental entrepreneur." My personal experience with infertility led me to co-found Calla Lily Clinical Care, where we are revolutionizing the way in which a range of gynecological conditions are managed, beginning with miscarriage prevention and fertility. With a broad background in clinical medicine and medical education in both the US and UK, I bring a unique understanding of the scientific, systematic and business challenges facing women's healthcare.